Tesa / Ipa Blend

• Tesamorelin

  The GHRH half: it tells the pituitary to release your own growth hormone

  • 10 mg · Vendor listings, unattributed
  Prescription
• Ipamorelin

  The ghrelin-receptor half: it suppresses somatostatin, the brake on that same release

  • 3 mg · Vendor listings, unattributed

• Tesamorelin: The GHRH half of the pair. Tesamorelin is a secretagogue rather than a hormone replacement: it binds GHRH receptors on the anterior pituitary and tells the gland to produce and release your own growth hormone, which drives IGF-1 and, through GH-mediated lipolysis, the loss of visceral fat specifically. Because the signal runs through the pituitary, the natural pulsatile pattern and the somatostatin feedback brake stay intact. It is the only compound in this library with an FDA approval aimed at visceral fat, and that approval is for the single-agent product rather than for anything blended. Our 2026 fact-check recorded a 10 mg / 3 mg pre-blend still being sold, which puts tesamorelin at 10 mg of a 13 mg vial. Worth knowing about the approved product for comparison, and only for comparison: the EGRIFTA labels dose tesamorelin at 1.28–1.4 mg daily, and they state that their own two formulations are not substitutable with each other. A figure from a label is not a figure for a blended vial.
• Ipamorelin: The ghrelin-receptor half, and the brake release. Ipamorelin activates GHS-R on the pituitary, which suppresses somatostatin, the hormone that normally stops growth hormone release. That is why the pair is sold together: one compound signals for release while the other removes the restraint, producing a larger pulse than either alone. Our sources describe ipamorelin as the most selective compound in its class, hitting the GH pathway without the cortisol, prolactin and appetite effects older ghrelin mimetics produce. Recorded at 3 mg of the same 13 mg vial. The ratio is what decides your ipamorelin dose, not you: at 10 mg / 3 mg in 2 mL of bacteriostatic water the vial holds tesamorelin 5 mg/mL and ipamorelin 1.5 mg/mL, so 20 units draws 1 mg tesamorelin and 300 mcg ipamorelin together. Change the draw to fix one and the other moves with it.

Duration

No cycle length is published for the blend by any source we can stand behind. The cadence sold alongside it (once daily in the evening, 5 days on and 2 off, 8 weeks on and 8 off) is vendor-tier and is not reproduced here as a schedule.

None of these is “the” composition. Switching vendors at the same product name and the same total milligrams can change a single component by 2×, with nothing on either label to tell you. That is why the only figure worth trusting here is the one on your own vial’s certificate of analysis.

The combined figure excludes Ipamorelin, for which our sources publish no price.

• Read the COA, not the name. This vial has no brand and no standard, so the ratio inside it is whatever your vendor mixed. Enter that composition and derive both doses from it.
• The ratio is the dose. In one barrel you cannot raise tesamorelin without raising ipamorelin by the same multiple, so the draw that puts one where you want it puts the other wherever the vendor decided.
• The tesamorelin label contraindications are hard, not cautions, and they do not soften because it arrived in a blend: disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumour or surgery, head irradiation, head trauma), active malignancy, hypersensitivity, and pregnancy.
• Both EGRIFTA labels state plainly: not indicated for weight loss management, and long-term cardiovascular safety is not established.
• The quantified label numbers are worth reading before starting. At 26 weeks, 47% of patients had IGF-1 above 2 standard deviations and 36% above 3. HbA1c reached 6.5% or higher in 5% of patients versus 1% on placebo. The intention-to-treat hazard odds ratio for developing diabetes was 3.3 (95% CI 1.4–9.6).
• FDA cites literature reports of serious adverse events including death when ipamorelin was given intravenously for gastric motility.
• This is two GH-axis compounds firing at once, in one injection. The Playbook warns explicitly against combining GH-modulating peptides without medical guidance.
• No stability study exists for these two peptides sharing a solution. Anyone telling you what a colour change means in this vial is telling you something nobody measured.
• Tesamorelin is a prescription compound. A blend is not a way around that.
• Both are on the WADA prohibited list under S2.

Absence from this list does NOT mean safety. It means lack of research.